Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome
| Autor: | Turgay Arinsoy, Ulver Derici, Kadriye Altok, Yasemin Erten, Galip Guz, Hasan Haci Yeter |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
Adult medicine.medical_specialty media_common.quotation_subject Renal function Gene mutation Antibodies Monoclonal Humanized Young Adult Internal medicine Atypical hemolytic uremic syndrome medicine Humans media_common Aged Atypical Hemolytic Uremic Syndrome Retrospective Studies business.industry Reproducibility of Results Retrospective cohort study Eculizumab Middle Aged medicine.disease Discontinuation Population study business medicine.drug |
| Zdroj: | Romanian journal of internal medicine = Revue roumaine de medecine interneREFERENCES. 60(1) |
| ISSN: | 2501-062X |
| Popis: | Introduction. The aim was to evaluate the effect of therapeutic plasma exchange (TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome (aHUS), and additionally, to examine the reliability of discontinuation of eculizumab treatment. Methods. This was an observational and retrospective study of 18 patients diagnosed with aHUS. Results. The median age of the study population was 30 (22–66) years. Four of 18 patients achieved hematological remission with the TPE alone. However, one patient died after three sessions of TPE. Eculizumab was used in 13 patients and no death was observed. One year after treatment, improved kidney function was observed in 2 of 3 (66%) patients for TPE and 5 of 9 (56%) patients for Eculizumab. We discontinued eculizumab treatment in 9 patients. One of the patients who had a C3 gene mutation experienced disease relapse after Eculizumab discontinuation. None of the patients who had drug associated aHUS developed disease relapse after Eculizumab discontinuation. Conclusion. Eculizumab treatment is a life-saving therapy in aHUS. Treatment discontinuation may be considered at least six months after hematologic remission in patients who had stable renal function or no expectancy for renal survival. Moreover, drug-associated cases seem to tend not to develop disease relapse in the long term. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|